Newsletters

12.13.23

FDA Receives Application for Approval of MDMA-Assisted Therapy

On December 12, 2023, the MAPS Public Benefit Corporation (MAPS PBC) announced the submission of a marketing application to the U.S. Food and Drug Administration (FDA) for MDMA (midomafetamine capsules) in combination with psychological intervention by a qualified health care provider (including ...


12.12.23

Trials & Tribulations: Removing Barriers to Participation in Clinical Trials to Advance Innovation

Through clinical trials, eligible patients can receive the latest cutting-edge treatments, which may not yet be available nationwide.


10.30.23

Achieving Clinical Trial Diversity: Expanding Hospital Capacity to Offer Trials in the Community

The inclusion of racial and ethnic groups in clinical trials has been a national priority for decades, but progress toward that end has been limited.


10.24.23

The Real Challenges That Stop Hospitals From Integrating Clinical Trials Into Clinical Care

A clinical trial infrastructure is often viewed as a cost rather than as a strategic investment. In any setting, to accrue more patients, organizations need a supporting and efficient infrastructure as well as a clinical practice culture that embraces research as part of their care delivery model.